

The Power of Choice in HR+, HER2- ABC

A Case Continuum

ESMO Breast Cancer Virtual Meeting 2020
Industry Satellite Symposium • 21 - 24 May 2020

Objectives

Discuss and increase awareness of recent advances and considerations in the treatment and management of HR+, HER2- ABC including:

- Overall survival data with CDK4/6 inhibitors
- Targeting PI3K and *PIK3CA* mutation testing
- Supporting patient care

Agenda

| | Topic | Faculty |
|--------|--|--|
| 5 min | Welcome and Introductions | Chair: Dejan Juric, MD |
| 5 min | Introduction of the Case | Dejan Juric, MD |
| 10 min | Presentation and Selection of a First-Line Therapy | Fatima Cardoso, MD |
| 5 min | Panel Discussion | Moderator: Dejan Juric, MD All Faculty Panel |
| 5 min | Spotlight Presentation: Fulvestrant as Combination Partner in Both First and Second Line | Dejan Juric, MD All Faculty Panel |
| 10 min | Switching to a Second-Line Treatment | Hans Christian Kolberg, MD |
| 5 min | Panel Discussion | Moderator: Dejan Juric, MD All Faculty Panel |
| 5 min | Putting the Case in Context | Dejan Juric, MD |
| 10 min | Panel Discussion: COVID-19 and Patient Management | Moderator: Dejan Juric, MD All Faculty Panel |



Evaluation Form

<https://www.surveymzmo.eu/s3/90233595/The-Power-of-Choice-in-HR-HER2-ABC-A-Case-Continuum-21-24-May-2020>

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program and/or material was developed for use outside of the US, intended for non-US HCPs, and is to be used in accordance with local laws and regulations.

Novartis Pharma AG
CH-4002 Basel Switzerland © Novartis 2020 02/20 G-RIB-1226985